ArticleNucleic acids research2026
Quantitative limits of host-driven HIV transcription and host gene control by the viral transactivator Tat.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
HIV transcription is amplified by the viral transactivator Tat, yet two quantitative issues remain unresolved in chromatin: the extent to which host machinery sustains transcription in the absence of Tat, and why Tat's widespread chromatin association yields limited host-gene output. We engineered an isogenic Tat-deficient derivative of the HIVGKO dual-reporter virus that preserves native proviral architecture, enabling longitudinal measurements across diverse integration sites in primary CD4⁺ T cells and Jurkat cells. Across thousands of proviruses, host factors alone supported a restricted baseline, with Tat-null proviruses producing ∼4%-15% of wild-type protein output and remaining constrained under strong stimulation. Chromatin immunoprecipitation-seq profiling revealed that Tat is dispensable for promoter-proximal RNAPII engagement and pausing but required for efficient CDK9 recruitment, Ser2 phosphorylation, and productive elongation, defining a ceiling for Tat-independent transcription. Tat deficiency reduced overall RNAPII occupancy without increased promoter-proximal accumulation. Genome-wide mapping using Tat-null controls revealed broad Tat association with active host loci and modest increases in elongation-factor occupancy; however, host-gene RNA gains were small (∼1.05-1.49×) and poorly correlated with Tat binding. Instead, elongation-associated chromatin features better predicted responsiveness. Together, these findings define a framework separating host-driven transcription from Tat-dependent scaling and explain Tat's disproportionate potency at the provirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.